Author: Vandana Singh

AstraZeneca’s GLP-1 Pill Heads To Late-Stage Trials

By Vandana Singh•

AstraZeneca Plc (NASDAQ:AZN) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies.

The findings, presented at the 2026 Scientific Sessions of the American Diabetes Association and published in The Lancet, support the company’s efforts to expand its cardiometabolic, renal, and weight-management portfolio.

Elecoglipron is an investigational oral, once-daily, small-molecule GLP-1 receptor agonist that mimics the natural GLP-1 hormone. 

VISTA Trial Demonstrates Significant Weight Reduction

The VISTA study enrolled 310 adults with obesity or overweight and at least one related comorbidity. Participants receiving elecoglipron 75 mg achieved an average body-weight reduction of 10.5% at 26 weeks, compared with 0.6% for placebo.

Weight loss continued through week 36, reaching 11.8% in the treatment group versus 0.3% with placebo.

The trial also met its co-primary endpoint measuring the proportion of participants achieving at least 5% weight loss, with up to 88.8% of patients on elecoglipron reaching that benchmark.

Researchers also reported improvements in exploratory cardiometabolic measures, including reductions in blood pressure and C-reactive protein, a marker of systemic inflammation.


Read Also:

Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages

SOLSTICE Trial Shows HbA1c And Weight Benefits

In the SOLSTICE trial, which enrolled 404 adults with Type 2 diabetes, elecoglipron achieved an average HbA1c reduction of 1.9% at 26 weeks, compared with 0.2% for placebo.

Most patients receiving the treatment reached guideline-recommended glycemic targets. By week 26, 90% recorded HbA1c levels below 7%, while 85% achieved HbA1c levels of 6.5% or lower.

The treatment also produced an average body-weight reduction of 7.7%, compared with 1.7% for placebo.

Safety Profile And Next Steps

Across both studies, adverse events were largely gastrointestinal and generally mild to moderate in severity. The most frequently reported events included nausea, constipation, diarrhea, and vomiting.

Discontinuations due to adverse events were uncommon, and investigators reported no liver safety signals. Hypoglycemia was infrequent in the diabetes study, with no serious cases linked to treatment.

The Phase 3 development plan includes the EMBOLD trials in obesity and overweight populations, as well as the ELUMINATE studies evaluating elecoglipron alone and in combination with dapagliflozin for Type 2 diabetes.

Additional studies will assess long-term cardiovascular and kidney outcomes.

AstraZeneca Price Action

AZN Stock Price Activity: AstraZeneca shares were up 0.73% at $182.88 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo via Shutterstock


Read Also:

‘Bitcoin Never Had A Chance’ Against The AI Bubble, Arthur Hayes Argues

Origin Materials Stock Craters As Board Moves To Sell Technology, Wind Down Operations

By Vandana Singh•

Origin Materials Inc. (NASDAQ:ORGN) shares are down on Monday following the company’s announcement of a strategic plan to sell its technology and wind down operations.

This news comes as the company aims to maximize shareholder value amid ongoing financial struggles.

The company engages in sustainable PET caps and closures.

Origin Materials Plans Technology Sale And Wind-Down

Origin Materials’ Board of Directors has approved a reduction in force to fund the continued qualification of customers and the strategic sale of its PET cap technology.

The company expects to wind down operations following these initiatives, with a plan for liquidation and dissolution pending shareholder approval.

As part of the reduction in force, members of the executive team will be leaving the company, with John Bissell stepping down as CEO while continuing to serve on the Board of Directors, and CFO and COO Matt Plavan appointed as interim CEO.

“Our ongoing work to support customer qualification processes and to optimize our products for manufacturing is a critical prerequisite to commercially scaling this technology, and continues to be our primary focus during this period,” Plavan commented.

“We previously reported that, absent near-term financing and reductions in operating expenses, our existing cash and cash equivalents would allow us to continue our planned operations into the third quarter of 2026,” Plavan further added.

In March, Origin Materials announced a 1-for-30 reverse stock split.

ORGN Price Action: Origin Materials shares were down 46.24% at $1.43 at the time of publication on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

Image via Shutterstock

NVIDIA Meets Healthcare – Roche To Build Massive AI Factory With NVIDIA To Speed Up Diagnostics, Therapies

By Vandana Singh•

Roche Holding AG (OTC:RHHBY) is ramping up its artificial intelligence capabilities with a large-scale AI “factory” powered by advanced computing from NVIDIA Corp. (NASDAQ:NVDA), aiming to accelerate drug development timelines and improve diagnostics across its global operations.

Roche Expands AI Infrastructure Across US And Europe

The Swiss pharmaceutical giant on Monday said the new infrastructure includes 2,176 high-performance GPUs deployed on premises across the U.S. and Europe.

Combined with its cloud capabilities, Roche’s total AI computing capacity now exceeds 3,500 Blackwell GPUs, marking one of the largest AI footprints disclosed by a pharmaceutical company.

The initiative builds on a strategic collaboration with NVIDIA that began in 2023, reflecting Roche’s push to integrate AI across its full value chain — from early discovery to commercialization.

Executives Highlight Speed And Innovation Benefits

Wafaa Mamilli, Roche’s Chief Digital and Technology Officer, emphasized the role of speed in healthcare innovation.

“In healthcare, time is the most critical variable,” Mamilli said, noting that faster development cycles can bring treatments to patients sooner.

The AI factory combines large-scale computing with Roche’s scientific expertise to streamline processes across research, manufacturing, and diagnostics, she added.

Roche AI Factory Targets Drug Discovery And Manufacturing Efficiency

Roche said the platform will support its “Lab-in-the-Loop” approach, where AI models are integrated with real-world biology and chemistry experiments. Using NVIDIA’s BioNeMo platform, scientists can test hypotheses at scale and accelerate discovery timelines.

In manufacturing, the company is deploying digital twins — virtual replicas of production systems — using NVIDIA Omniverse tools to optimize factory design and operations.

The infrastructure also enhances diagnostics, with AI-powered tools analyzing large datasets and identifying subtle disease patterns through digital pathology systems.

Genentech R&D Head Sees Faster Path To Medicines

Aviv Regev, head of Genentech Research and Early Development, said the expanded computing power will enable more advanced predictive models.

Regev added that scaling Roche’s Lab-in-the-Loop strategy could significantly shorten the timeline from biological insights to life-saving treatments.

New Timeline For Residual Cancer Detection

In March, Droplet Biosciences, a diagnostics company developing lymph-based liquid biopsy tests, announced a collaboration with NVIDIA to detect residual cancer within 24 hours of surgery — weeks earlier than traditional blood-based monitoring.

Unlike conventional minimal residual disease (MRD) tests that rely on blood plasma weeks after surgery, Droplet collects lymphatic fluid just 24 hours after tumor removal.

Image Via Shutterstock

FDA Delays Disc Medicine’s Rare Disease Drug

By Vandana Singh•

Disc Medicine Inc. (NASDAQ:IRON) shares closed around 22% lower on Friday as the company navigates a regulatory hiccup with a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its drug bitopertin. On Tuesday, the stock is trading higher.

Bitopertin has been under review for accelerated approval and as part of the Commissioner’s National Priority Voucher (CNPV) pilot program.

In January, FDA reviewers postponed their decision on bitopertin by about two weeks to February 10.

Regulators questioned whether “pain-free time in the sun,” a secondary endpoint in trials, was a statistically reliable measure of effectiveness or whether biomarker data could instead support approval.

FDA Block

The FDA issued a CRL for Disc Medicine’s New Drug Application for bitopertin, which is aimed at treating erythropoietic protoporphyria (EPP), a rare disease that causes extreme sensitivity to sunlight.

The agency concluded that while the clinical trials provided evidence of the drug’s efficacy in lowering whole blood metal-free PPIX, they did not demonstrate a clear association with clinical benefits, which has delayed the approval process.

The company on Friday said that accelerated approval relies on whether there is evidence of an effect on the proposed surrogate endpoint (% change in whole blood metal-free PPIX) and whether the proposed surrogate endpoint, including the magnitude of change, is reasonably likely to predict a clinical benefit.

On the first point, the FDA agreed that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers whole blood metal-free PPIX.

On the second, based on review of AURORA and BEACON results, the FDA concluded that the trials did not show evidence of association between percent change in PPIX and sunlight exposure-based endpoints, despite the strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyria.

The FDA indicated that the results of the APOLLO study could serve as evidence to support traditional approval.

In response to the CRL, Disc Medicine expressed confidence in its ongoing APOLLO trial, which is expected to yield topline data in the fourth quarter of 2026.

The company plans to request a Type A meeting with the FDA to discuss the next steps. Disc maintains a cash position of approximately $791 million as of December 31, 2025, and guidance of providing runway into 2029.

Technical Analysis

Currently, the stock is trading 4.4% above its 20-day simple moving average (SMA) and 2.2% below its 100-day SMA, indicating some short-term strength but potential resistance at longer-term averages. Over the past 12 months, shares have increased by 2.42%, and they are currently positioned closer to their 52-week highs than lows, suggesting a relatively strong performance.

The RSI is at a neutral level, indicating that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is below its signal line, suggesting bearish pressure on the stock.

The combination of neutral RSI and bearish MACD indicates mixed momentum for Disc Medicine at this time.

  • Key Resistance: $60.00
  • Key Support: $55.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $102.00. Recent analyst moves include:

  • Wells Fargo: Overweight (Raises Target to $109)
  • Truist Securities: Buy (Raises Target to $114)
  • Stifel: Buy (Target $125)

IRON Price Action: Disc Medicine shares were up 4.40% at $58.41 during premarket trading on Tuesday, according to Benzinga Pro data.

Photo by Tada Images via Shutterstock

White House Readies Drug Price Deals With AbbVie, Novartis, Roche

By Vandana Singh•

AbbVie Inc. (NYSE:ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with additional policy demands from President Donald Trump.

Reuters on Tuesday highlighted that around five companies are expected to be included in the initial announcement.

In September, Pfizer Inc. (NYSE:PFE) announced the first agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines.

The administration is also set to outline a pilot program that would link Medicare drug payments to the lowest prices charged by manufacturers in a group of comparable foreign markets.

Also Read: AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report

Who Is Cutting Deals?

In July, Trump sent letters to 17 major pharmaceutical companies calling for “most-favored-nation” pricing for Medicaid, limits on U.S. launch prices relative to other high-income countries, increased domestic reinvestment, and expanded direct-to-consumer sales models.

Five companies—Pfizer, Eli Lilly and Co (NYSE:LLY), AstraZeneca Plc (NASDAQ:AZN), Novo Nordisk A/S (NYSE:NVO), and EMD Serono Merck KGaA’s (OTC:MKGAF) (OTC:MKKGY) U.S. unit—have already agreed to the terms.

The remaining companies yet to sign on include Sanofi SA (NASDAQ:SNY), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Merck & Co Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), AbbVie, Amgen Inc. (NASDAQ:AMGN), Gilead Sciences Inc. (NASDAQ:GILD), Boehringer Ingelheim, Bristol Myers Squibb & Co (NYSE:BMY), GSK Plc (NYSE:GSK), Novartis AG (NYSE:NVS), and Genentech, Roche Holdings AG’s (OTC:RHHBY) U.S. unit.

Drug Price Gap Between USA And Global

Trump has repeatedly targeted the gap between U.S. drug prices and those in other developed countries, where government-run health systems negotiate prices before granting reimbursement.

On Tuesday, Bloomberg also reported that the White House is preparing to announce drug pricing agreements with Novartis and Roche as soon as Friday, a move that could further ease recent trade tensions with Switzerland following a tariff dispute.

Sources told Bloomberg that additional drugmakers may be included, though terms are still being finalized.

Switzerland last month secured a preliminary trade deal cutting tariffs on several domestic exports, including watches, to 15% from 39%, after facing the steepest levy imposed on any developed country. While pharmaceuticals were exempt from those tariffs, the administration had signaled the possibility of future duties.

Novartis told Bloomberg that it is in discussions with the administration and is focused on lowering U.S. drug costs while addressing pricing gaps between the U.S. and other high-income markets.

Price Action: Novartis shares were up 0.34% at $135.49, and AbbVie shares were up 0.36% at $225.11 at the time of publication on Thursday, according to Benzinga Pro data.

Read Next:

Photo via Shutterstock

Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook

By Vandana Singh•

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.

Pfizer’s sales jumped 10% year over year to $14.70 billion, above the consensus of $13.41 billion, reflecting an operational increase of 10%.

The operational increase was primarily driven by an increase in revenues for the Vyndaqel family, Comirnaty, Paxlovid, Padcev, Eliquis, and several other products across categories, despite the unfavorable impact of higher manufacturer discounts resulting from the Inflation Reduction Act (IRA) Medicare Part D Redesign.

Also Read: Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook

Heart drug Vyndaqel family sales increased 21% operationally, to $1.62 billion.

Comirnaty sales were $381 million, up 95% operationally, and Paxlovid sales were up 71% operationally to $427 million.

Cancer drug Padcev sales jumped 38% to $542 million.

Blood thinner Eliquis revenues increased 6% operationally to around $2 billion.

The company’s revenue growth was offset by lower sales from its breast cancer drug, Ibrance, of $1.05 billion, down 8% operationally.

The drug had a lower U.S. net price largely due to the impact of higher manufacturer discounts from provisions of the Inflation Reduction Act that redesign Medicare Part D benefits, as well as generic competition and the timing of shipments in certain international markets.

Outlook

Pfizer reaffirms its 2025 revenues guidance of $61 billion—$64 billion, compared to the consensus of $62.42 billion. T

he company raises its 2025 adjusted earnings per share guidance from $2.80-$3.00 to $2.90-$3.10, compared to the Wall Street estimate of $3. The revised outlook includes a one-time impact of approximately 20 cents related to the 3SBio transaction.

Pfizer adds that the guidance absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico, as well as potential price changes this year based on the letter received on July 31 from President Trump.

Cost-Cutting Initiatives

Pfizer said it is on track to deliver approximately $7.7 billion in anticipated overall savings (approximately $7.2 billion of net cost savings). Approximately $4.5 billion of overall net cost savings from Pfizer’s ongoing cost realignment program are expected to be achieved by the end of 2025.

The company is on track to deliver anticipated R&D reorganization cost savings of approximately $500 million to be fully realized by the end of 2026.

The first phase of the Manufacturing Optimization Program is on track to deliver approximately $1.5 billion in net cost savings by the end of 2027, with initial savings anticipated in the latter part of 2025.

Price Action: PFE stock is up 4.12% at $24.50 at the last check on Tuesday.

Read Next:

Photo via Shutterstock

Aurora Cannabis Stock Jumps On ‘Record-Breaking’ Q3 Earnings

By Vandana Singh•

Canada-based global medical cannabis company Aurora Cannabis Inc (NASDAQ:ACB) reported a third-quarter fiscal 2025 net revenue of CA$88.2 million, compared to CA$64.4 million a year ago.

The 37% increase from the prior period was mainly due to 51% growth in the global medical cannabis business and 22% in the plant propagation business, slightly offset by lower quarterly revenue in the consumer cannabis business.

Consolidated adjusted gross margin was 65% in the third quarter and 53% in the prior-year quarter. Adjusted gross profit was CA$56.0 million in the third quarter vs. CA$33.6 million in the prior year quarter, an increase of 67%.

Also Read: The Week In Cannabis: Trump’s DEA Pick, Tyson’s Reform Push, Dutch Coffee Shop Crisis And More

Medical cannabis net revenue was CA$68.1 million, a 51% increase from the prior-year quarter, driven by CA$23.1 million was primarily due to higher sales to Australia, Germany, Poland and the UK, as well as increased revenue in Canada to insurance covered and self-paying patients.

The adjusted gross margin reached 74%, compared to 63% in the prior year quarter, through sustainable cost reductions, higher selling prices, and improved efficiency in production operations, including sourcing for Europe from Canada.

Aurora’s consumer cannabis net revenue was CA$9.9 million, a 15% decrease compared to $11.6 million in the prior year quarter, mainly due to the decision to prioritize the supply of GMP manufactured products to high-margin global medical cannabis business rather than the consumer business, which offers lower margins.

Plant propagation net revenue contributed $8.9 million, a 22% increase compared to $7.3 million a year ago, due to organic growth and expanded product offerings arising from increased capacity.

Adjusted EBITDA increased 316% to CA$23.1 million compared to CA$5.5 million a year ago.

“This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow,” said Miguel Martin, executive chairman and CEO for Aurora Cannabis.

Fiscal Q4 2025 Expectations:

  • Revenue is expected to grow, driven by international medical cannabis sales.
  • Seasonal increase in plant propagation revenue, following usual trends.
  • Strong profit margins and continued positive adjusted EBITDA.
  • Lower operating cash use due to disciplined spending and revenue growth.
  • Free cash flow should be slightly positive as cash use improves.

Price Action: ACB stock is up 31.3% at $4.83 during the premarket session at last check Wednesday.

Read Next:

European And US Vaccine Stocks Are Under Pressure – Here’s WHy

By Vandana Singh•

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services.

Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have debunked this theory.

Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy being in charge.

Kennedy, who received Trump’s blessing to “go wild on health,” has stated intentions to overhaul various aspects of the federal health agencies.

In a post on social media, Kennedy said, “Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.”

On Friday, the World Health Organization also defended vaccines describing them as “absolutely critical” to global health, adding that many people alive today would not have survived childhood without them.

European vaccine player stocks declined, including GSK Plc (NYSE:GSK), Valneva SE (NASDAQ:VALN), AstraZeneca Plc (NASDAQ:AZN), BioNTech SE (NASDAQ:BNTX), and Sanofi SA (NASDAQ:SNY).

GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline in vaccine sales.

COVID-19 vaccine players Moderna Inc (NASDAQ:MRNA), Pfizer Inc (NYSE:PFE), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.

Other vaccine players’ stocks that are down include Merck & Co Inc (NYSE:MRK) and Inovio Pharmaceuticals, Inc (NASDAQ:INO).

Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.

Read Next:

Photo by Vladimka production via Shutterstock

Nvidia Partners With Startup Aidoc To Accelerate Healthcare AI Adoption

By Vandana Singh•

Nvidia Corp (NASDAQ:NVDA) announced that it will partner with Aidoc, a startup that offers healthcare organizations artificial intelligence (AI) tools to improve workflows, data accuracy, and overall patient care.

The companies will work on a new framework, “Blueprint for Resilient Integration and Deployment of Guided Excellence” (BRIDGE),  a guideline that aims to accelerate AI adoption across the healthcare industry.

Also Read: Microsoft Unveils Health Care AI Tools To Help Analyze Biomedical Data.

The guideline, scheduled for release in early 2025, will introduce a comprehensive, evidence-based framework for more effectively integrating AI into clinical workflows.

It aims to enable healthcare organizations to accelerate AI innovation with increased confidence. The guideline will outline strategies for healthcare systems to fully leverage AI’s potential in enhancing patient outcomes.

Although more than 900 FDA-cleared AI tools for medical imaging have been approved, healthcare systems still face fragmentation, operational inefficiencies, and scalability challenges.

The BRIDGE guideline will offer a vendor-neutral, all-encompassing roadmap to tackle these issues, empowering providers to realize AI’s benefits fully.

“AI holds the potential to revolutionize patient care, but its progress has been stalled by fragmented systems and the inability to scale effectively,” said Demetri Giannikopoulos, Chief Transformation Officer, Aidoc. “The BRIDGE guideline will focus on breaking down these barriers, offering a powerful, evidence-based framework that health systems can rely on not just adopt AI but to help scale it across their operations. This will drive both operational efficiency and significantly better outcomes for patients and clinicians alike.”

The BRIDGE guideline aims to establish a foundation aligned with industry frameworks like MONAI, which will serve as the blueprint for the medical AI enterprise platform.

MONAI, co-founded in 2019 by academia and industry leaders, including NVIDIA, offers essential tools for developing, validating, and deploying medical AI.

With over three million downloads and active use in FDA-approved software-as-medical-device applications, MONAI’s emphasis on standardization, interoperability, and scalability is crucial to driving transformative healthcare solutions.

Price Action: NVDA stock is up 0.32% at $138.32 at last check Monday.

Read Next:

Photo by PopTika on Shutterstock

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

By Vandana Singh•

Thursday, Johnson & Johnson (NYSE:JNJ) announced the submission of a Biologics License Application (BLA) to the FDA seeking the first approval of nipocalimab globally for generalized myasthenia gravis (gMG). 

gMG is an autoantibody-driven neuromuscular disease characterized by fluctuating muscle weakness.

The update marks the first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce autoantibody levels.

Also Read: Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy.

The application included data from the Phase 3 Vivacity-MG3 study, which showed that outcomes for a broad population of antibody-positive participants who received nipocalimab plus standard of care (SOC) were superior compared to those who received placebo plus SOC.

In the Phase 3 VIVACITY study in gMG, nipocalimab met the primary endpoint, achieving a statistically significant reduction in MG-ADL score from baseline over weeks 22 to 24 compared with placebo. 

Earlier this year, at the American Academy of Neurology Annual Meeting, Johnson & Johnson presented data on the molecular properties of nipocalimab.

Last year, the FDA approved UCB SA’s (OTC:UCBJF) (OTC:UCBJY)

Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

The company says Rystiggo is the only FDA-approved treatment in adults for anti-AChR and anti-MuSK antibody-positive gMG, the two most common subtypes of gMG.

Johnson & Johnson’s drug will also compete with Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo for gMG in adult patients who are anti-acetylcholine receptor antibody positive. 

The drug is available in subcutaneous and intravenous injections.

Price Action: JNJ stock is up 0.36% at $164.51 at the last check on Thursday.

Read Next:

Image By Sundry Photography Via Shutterstock